Latest news

Regulatory

FDA Grants Full Approval to Fabhalta for IgA Nephropathy

Novartis has received full approval from the U.S. Food and Drug Administration (FDA ) for Fabhalta to treat adults...
Clinical

After phase 3 data ended blockbuster hopes, GSK eliminated a major cough medication candidate

Analysis of the phase 3 results on camlipixant, which was a major potential blockbuster expected to be the standout...
Commercial

Dimerix Acquires Phase 2-Ready AKI Drug DMX-652 From Mission Therapeutics

Dimerix has acquired DMX-652, a phase 2-ready drug candidate for acute kidney injury (AKI), from Mission Therapeutics in a...
Insights

Top 10 Strategic Priorities for Pharmaceutical Leaders in 2026

Executive Summary The pharmaceutical industry is entering a period of profound transformation. While scientific innovation remains the foundation of long-term...
Commercial

Lilly challenges J&J in the market for psychedelic mental health by paying $2.8 billion up front for AtaiBeckley

Eli Lilly has inked the deal to purchase AtaiBeckley...
Insights

The Next Wave of Innovation in Oncology

Executive Summary Oncology remains one of the most dynamic and...
Commercial

GSK will increase its R&D efforts by investing £400 million in Britain over three years

British pharmaceutical and biotechnology firm GSK has announced a comprehensive investment plan in the United Kingdom's pharmaceutical and biotechnology...
Clinical

Hansoh Announces Fresh Phase 3 Victory For Priority ADC

Hansoh Pharmaceutical has recorded another late-stage success for its B7-H3-targeting antibody-drug conjugate (ADC), developed in partnership with GSK, after...
Clinical

Altimmune Reports Phase 2 Pemvidutide Results in Alcohol Use Disorder

Altimmune has reported topline results from its Phase 2 RECLAIM trial evaluating pemvidutide, an investigational dual GLP-1/GIP receptor agonist,...
Commercial

Included Health Agrees to Acquire Firefly Health to Expand Employer Health Plan Alternatives

Virtual care and health navigation company Included Health has...
Insights

The Workforce Challenge Facing Biopharma Manufacturing

Executive Summary Biopharmaceutical manufacturing is entering one of the most...
Commercial

Argenx purchases Forte for $2.2 billion to enter the hands-on phase two-stage medication for vitiligo

Forte Biosciences is being acquired by Argenx for $2.2 billion in a deal that has two stages: phase 2...
Insights

What Pharma Leaders Are Prioritizing in 2026

Executive Summary The pharmaceutical industry is entering a new phase of transformation. While scientific innovation remains the foundation of long-term success,...
Regulatory

Takeda’s Qdenga Makes History as First Vaccine to Get the Nod in India

Takeda has secured approval from the Drug Controller General of India (DCGI) for Qdenga, making it the first vaccine...
Regulatory

FDA Grants Full Approval to Fabhalta for IgA Nephropathy

Novartis has received full approval from the U.S. Food...
Editorial Team -
Commercial

Dimerix Acquires Phase 2-Ready AKI Drug DMX-652 From Mission Therapeutics

Dimerix has acquired DMX-652, a phase 2-ready drug candidate...
Editorial Team -

Popular

Most popular life news you must read today

View all articles

Commercial

Information Technology

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

The U.S. Food and Drug Administration (FDA) granted Johnson & Johnson De Novo clearance...
Editorial Team -

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Alnylam has entered into a partnership with the scientist instrumental in developing the technology...
Editorial Team -

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

Chugai Pharmaceutical has entered into a research collaboration with Singapore-based Gero to develop antibody-based...
Editorial Team -

J&J MedTech presents the first Ottava surgical robot clinical cases

Johnson & Johnson MedTech successfully conducted the initial clinical use of Ottava surgical robot...
Editorial Team -

Regulatory

Regulatory

FDA Grants Full Approval to Fabhalta for IgA Nephropathy

Novartis has received full approval from the U.S. Food...
Editorial Team -
Clinical

After phase 3 data ended blockbuster hopes, GSK eliminated a major cough medication candidate

Analysis of the phase 3 results on camlipixant, which...
Commercial

Dimerix Acquires Phase 2-Ready AKI Drug DMX-652 From Mission Therapeutics

Dimerix has acquired DMX-652, a phase 2-ready drug candidate...
Insights

Top 10 Strategic Priorities for Pharmaceutical Leaders in 2026

Executive Summary The pharmaceutical industry is entering a period of...
Insights

Why Data Quality Is Becoming Pharma’s Biggest AI Challenge

Executive Summary Artificial intelligence (AI) has become one of the...

Research & Development

Market Access

Manufacturing

Avalyn Files for IPO Targeting Up to $209.7 Million to Advance Inhaled Lung Therapies

Avalyn Pharma, a Boston-based company focused on inhaled therapies...
Manufacturing

Replimune Cuts 224 Jobs in Massachusetts After Second FDA Rejection of RP1

Replimune is reducing its workforce by 224 employees across...

Manufacturing & RegulatoryPOPULAR
Find Your Perfect Music Festival

Regulatory

FDA Grants Full Approval to Fabhalta for IgA Nephropathy

Novartis has received full approval from the U.S. Food...
Editorial Team -
Commercial

Dimerix Acquires Phase 2-Ready AKI Drug DMX-652 From Mission Therapeutics

Dimerix has acquired DMX-652, a phase 2-ready drug candidate...
Editorial Team -